CSIMarket
 
Evolus Inc   (EOLS)
Other Ticker:  
 
 
Price: $16.7700 $-0.72 -4.117%
Day's High: $17.7 Week Perf: 10.47 %
Day's Low: $ 16.54 30 Day Perf: 23.31 %
Volume (M): 754 52 Wk High: $ 17.70
Volume (M$): $ 12,646 52 Wk Avg: $11.76
Open: $17.58 52 Wk Low: $7.44



 Market Capitalization (Millions $) 1,052
 Shares Outstanding (Millions) 63
 Employees 130
 Revenues (TTM) (Millions $) 237
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) 52
 Capital Exp. (TTM) (Millions $) 3

Evolus Inc
Evolus Inc is a biotechnology and aesthetics company that is headquartered in Newport Beach, California. The company specializes in the development and commercialization of medical products that improve the appearance and well-being of individuals. Evolus Inc was founded in 2012 by a team of healthcare professionals and biotech industry veterans who had a vision of transforming the aesthetic industry through innovation.

One of Evolus Inc's flagship products is Jeuveau, a prescription medicine that is used to improve the appearance of frown lines between the eyebrows in adults. Jeuveau is a botulinum toxin type A injectable that works by blocking the nerve signals that cause muscles to contract. The treatment temporarily relaxes the muscles, thereby smoothing out the wrinkles and lines on the face. Jeuveau was approved by the US Food and Drug Administration (FDA) in 2019 and is the first new botulinum toxin approved for aesthetics in over a decade.

Evolus Inc is also actively engaged in the research and development of new medical products for aesthetics and other therapeutic areas. The company has a robust pipeline of programs in various stages of development, including biosimilars, topical formulations, and neurotoxins. Evolus Inc has a strong focus on using advanced technologies to improve the safety, efficacy, and convenience of its products.

In addition to its core operations, Evolus Inc is committed to advancing the aesthetics industry through education and collaboration. The company partners with healthcare providers and industry experts to advance best practices and promote patient safety. It also supports research initiatives that seek to better understand the science behind aging and aesthetics.

Evolus Inc is led by a team of seasoned executives with extensive experience in the biotech and aesthetics industries. The company is publicly traded on the NASDAQ stock exchange and has a global reach through its partnerships with distributors and healthcare providers. Evolus Inc has earned recognition for its innovative products, commitment to quality, and dedication to improving patient outcomes.


   Company Address: 520 Newport Center Drive Suite 1200 Newport Beach 92660 CA
   Company Phone Number: 284-4555   Stock Exchange / Ticker: NASDAQ EOLS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

In the ever-evolving realm of aesthetics and consumer beauty, Evolus, Inc. (NASDAQ EOLS) emerges as a formi...

Published Wed, Jul 31 2024 2:47 PM UTC

'Evolus Inc.: A Dynamic Future in Performance Beauty Unfolds with Upcoming Investor Day and Positive Pivotal Study Results' In the ever-evolving realm of aesthetics and consumer beauty, Evolus, Inc. (NASDAQ: EOLS) emerges as a formidable player, demonstrating a sustainable commitment to innovation and strategic growth. The company recently announced significant developments ...

Business Update

Evolus Advances Aesthetic Innovation with PMA Submission for Dermal Fillers Amidst Record Financial Growt...

Published Mon, Jun 24 2024 12:47 PM UTC

'Newport Beach, Calif.' - Evolus, Inc. (NASDAQ: EOLS), a performance beauty company dedicated to creating a portfolio of aesthetic consumer brands, has made a significant stride in its strategic growth plan. The company announced the submission of the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its first two Evo...

Business Update

Evolus, Inc., a renowned performance beauty company, recently announced the positive topline results from a pivotal study of their dermal filler products, Evolysse Lift and Smooth. This achievement marks a significant milestone for the company and reinforces their commitment to developing an aesthetic portfolio of consumer brands. The data from this study were presented at...

Published Mon, May 20 2024 12:47 PM UTC

Promising Results of Evolus' Evolysse Dermal Filler Products: A Breakthrough in Nasolabial Fold Treatment Evolus, Inc., a renowned performance beauty company, recently announced the positive topline results from a pivotal study of their dermal filler products, Evolysse Lift and Smooth. This achievement marks a significant milestone for the company and reinforces their commit...

Evolus Inc

Evolus Inc Shines with 42% Revenue Surge in First Quarter Despite Net Loss

As a financial analyst for the CSIMarket.com, I have been closely monitoring Evolus Inc's first quarter financial results and analyzing the company's performance in the performance beauty industry. Despite reporting a net loss of $-0.22 per share in the January to March 31 span, Evolus Inc showcased a significant revenue surge of 42.214% to $59.33 million compared to the same reporting season a year prior.
The company's revenue increase demonstrates Evolus Inc's strong market demand and the effectiveness of its strategic initiatives in driving growth. Additionally, Evolus Inc was able to reduce its net deficit from $-14.791 million to $-13.109 million in the first quarter of 2024, indicating improvements in the company's financial health.

Business Update

Evolus Reports Impressive First Quarter 2024 Results and Positive Business Outlook

Published Tue, May 7 2024 9:47 PM UTC

Evolus, Inc., a leading performance beauty company focused on developing a portfolio of aesthetic consumer brands, has recently announced its financial results for the first quarter ended March 31, 2024. Following a record-breaking year in 2023, the company continues to exhibit impressive growth and promising business prospects. This article will delve into Evolus' noteworth...







Evolus Inc's Segments

  Evolus Inc Outlook

On March 7 2024 the Evolus Inc provided following guidance

Evolus Inc, a performance beauty company known for its customer-centric approach and breakthrough products, has reported record-breaking financial results for the fourth quarter and full year of 2023. The company, listed on the NASDAQ under the ticker symbol EOLS, saw significant growth in market share throughout the year, solidifying its position as the fastest-growing toxin in the U.S. for the third consecutive year.

In addition to its success in the U.S. market, Evolus also expanded its portfolio globally by introducing an innovative late-stage product. This expansion has allowed the company to reach new markets and further establish itself as a leader in the beauty industry.

Looking ahead ...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com